Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis

被引：0
|
作者：
Goodman, A. D.
Brown, T.
Krupp, L.
Schapiro, R.
Marinucci, L.
Cohen, R.
Blight, A.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis
    Goodman, Andrew D.
    Brown, Ted R.
    Edwards, Keith R.
    Schapiro, Randall T.
    Marinucci, Lawrence N.
    Cohen, Ron
    Blight, Andrew R.
    NEUROLOGY, 2010, 74 (09) : A101 - A101
  • [2] Interim analysis: Open-label extension study of leniolisib for patients with APDS
    Rao, V. Koneti
    Kulm, Elaine
    Sediva, Anna
    Plebani, Alessandro
    Schuetz, Catharina
    Shcherbina, Anna
    Dalm, Virgil A.
    Trizzino, Antonino
    Zharankova, Yulia
    Webster, Sharon
    Orpia, Alanvin
    Koeurorholz, Julia
    Lougaris, Vassilios
    Rodina, Yulia
    Radford, Kath
    Bradt, Jason
    Relan, Anurag
    Holland, Steven M.
    Lenardo, Michael J.
    Uzel, Gulbu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 265 - 274.e9
  • [3] Updated analysis of open-label extension studies of dalfampridine extended release tablets in multiple sclerosis
    Goodman, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S245 - S246
  • [4] Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
    Okuda, Darin T.
    Kantor, Daniel
    Jaros, Mark
    de Vries, Tina
    Hunter, Samuel
    BRAIN COMMUNICATIONS, 2022, 5 (01)
  • [5] Sustained-release fampridine in Multiple Sclerosis
    Hadavi, S.
    Baker, M. D.
    Dobson, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (01) : 17 - 21
  • [6] Sustained-release fampridine for multiple sclerosis
    Bever, Christopher T., Jr.
    Judge, Susan I. V.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 1013 - 1024
  • [7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [8] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [9] Pharmacokinetics and Tolerability of Single Escalating Doses of Fampridine Sustained-Release Tablets in Patients With Multiple Sclerosis: A Phase I-II, Open-Label Trial
    Vollmer, Timothy
    Henney, Herbert R., III
    CLINICAL THERAPEUTICS, 2009, 31 (10) : 2206 - 2214
  • [10] Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension
    Kondo, T.
    Kawachi, I
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Matta, A.
    Torii, S.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (03)
12345